During the recent session, Avenue Therapeutics Inc (NASDAQ:ATXI)’s traded shares were 18.34 million, with the beta value of the company hitting -0.27. At the last check today, the stock’s price was $1.71, reflecting an intraday loss of -7.09% or -$0.13. The 52-week high for the ATXI share is $15.00, that puts it down -777.19 from that peak though still a striking 6.43% gain since the share price plummeted to a 52-week low of $1.60. The company’s market capitalization is $3.51M, and the average intraday trading volume over the past 10 days was 91100.0 shares, and the average trade volume was 50.44K shares over the past three months.
Avenue Therapeutics Inc (ATXI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ATXI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Avenue Therapeutics Inc (NASDAQ:ATXI) trade information
Avenue Therapeutics Inc (ATXI) registered a -7.09% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.09% in intraday trading to $1.71, hitting a weekly high. The stock’s 5-day price performance is -2.31%, and it has moved by -3.41% in 30 days. Based on these gigs, the overall price performance for the year is -83.82%. The short interest in Avenue Therapeutics Inc (NASDAQ:ATXI) is 50925.0 shares and it means that shorts have 0.73 day(s) to cover.
The consensus price target of analysts on Wall Street is $12, which implies an increase of 85.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $12 respectively. As a result, ATXI is trading at a discount of -601.75% off the target high and -601.75% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 50.07%. While earnings are projected to return 91.51% in 2025.
ATXI Dividends
Avenue Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Avenue Therapeutics Inc (NASDAQ:ATXI)’s Major holders
Avenue Therapeutics Inc insiders own 9.85% of total outstanding shares while institutional holders control 10.33%, with the float percentage being 11.46%.
Also, the Mutual Funds coming in first place with the largest holdings of Avenue Therapeutics Inc (ATXI) shares are Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund. Data provided on Nov 30, 2024 indicates that Fidelity Extended Market Index Fund owns about 6.59 shares. This amounts to just over 0.32 percent of the company’s overall shares, with a $11537.0 market value. The same data shows that the other fund manager holds slightly less at 1.58, or about 0.08% of the stock, which is worth about $2772.0.
